KR20010014316A - 8-클로로-6,11-디하이드로-11-(4-피페리딜리덴)-5Ｈ-벤조[5,6]사이클로헵타[1,2-ｂ]피리딘의 동질이상체 - Google Patents
8-클로로-6,11-디하이드로-11-(4-피페리딜리덴)-5Ｈ-벤조[5,6]사이클로헵타[1,2-ｂ]피리딘의 동질이상체 Download PDFInfo
- Publication number
- KR20010014316A KR20010014316A KR1019997012456A KR19997012456A KR20010014316A KR 20010014316 A KR20010014316 A KR 20010014316A KR 1019997012456 A KR1019997012456 A KR 1019997012456A KR 19997012456 A KR19997012456 A KR 19997012456A KR 20010014316 A KR20010014316 A KR 20010014316A
- Authority
- KR
- South Korea
- Prior art keywords
- vwd
- crystalline
- isoform
- approximately
- frequency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 title abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 4
- 102000001708 Protein Isoforms Human genes 0.000 claims description 50
- 108010029485 Protein Isoforms Proteins 0.000 claims description 50
- 239000002480 mineral oil Substances 0.000 claims description 17
- 235000010446 mineral oil Nutrition 0.000 claims description 16
- 238000002329 infrared spectrum Methods 0.000 claims description 15
- 230000003266 anti-allergic effect Effects 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000009792 diffusion process Methods 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 16
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 16
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002798 spectrophotometry method Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- -1 alkanes ethers Chemical class 0.000 description 4
- 230000001387 anti-histamine Effects 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002362 mulch Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- HTSABYAWKQAHBT-UHFFFAOYSA-N trans 3-methylcyclohexanol Natural products CC1CCCC(O)C1 HTSABYAWKQAHBT-UHFFFAOYSA-N 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88676697A | 1997-07-02 | 1997-07-02 | |
| US08/886,766 | 1997-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010014316A true KR20010014316A (ko) | 2001-02-26 |
Family
ID=25389724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019997012456A Ceased KR20010014316A (ko) | 1997-07-02 | 1998-07-01 | 8-클로로-6,11-디하이드로-11-(4-피페리딜리덴)-5Ｈ-벤조[5,6]사이클로헵타[1,2-ｂ]피리딘의 동질이상체 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0993455B1 (https=) |
| JP (2) | JP2002507991A (https=) |
| KR (1) | KR20010014316A (https=) |
| CN (1) | CN1261886A (https=) |
| AR (1) | AR013161A1 (https=) |
| AT (1) | ATE239010T1 (https=) |
| AU (1) | AU734487B2 (https=) |
| BR (1) | BR9811658A (https=) |
| CA (1) | CA2294352C (https=) |
| CO (1) | CO4940423A1 (https=) |
| DE (1) | DE69814076T2 (https=) |
| ES (1) | ES2197480T3 (https=) |
| HU (1) | HUP0004308A3 (https=) |
| IL (1) | IL133387A (https=) |
| MY (1) | MY132943A (https=) |
| NO (1) | NO996547L (https=) |
| NZ (1) | NZ501417A (https=) |
| PE (1) | PE86399A1 (https=) |
| PL (1) | PL337712A1 (https=) |
| RU (1) | RU2197485C2 (https=) |
| SK (1) | SK185299A3 (https=) |
| TR (1) | TR199903308T2 (https=) |
| UA (1) | UA62976C2 (https=) |
| WO (1) | WO1999001450A1 (https=) |
| ZA (1) | ZA985783B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
| US7678908B2 (en) * | 2002-04-15 | 2010-03-16 | Sun Pharmaceutical Industries Limited | Process of preparing desaloratadine |
| WO2004012738A1 (en) * | 2002-08-05 | 2004-02-12 | Sandoz Ag | Novel salt and polymorphs of desloratadine hemifumarate |
| US20060135547A1 (en) * | 2003-03-12 | 2006-06-22 | Toth Zoltan G | Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine |
| WO2004080461A2 (en) * | 2003-03-12 | 2004-09-23 | TEVA Gyógyszergyár Részvénytársaság | Stable pharmaceutical compositions of desloratadine |
| SK50112007A3 (sk) * | 2004-07-07 | 2007-07-06 | Egis Gy�gyszergy�r Nyrt. | Nový pseudopolymorf desloratadínu vytvorený s oxidom uhličitým |
| TW200735871A (en) * | 2005-11-17 | 2007-10-01 | Teva Pharma | Desloratadine crystalline forms mixtures having a low level of residual solvents |
| HU230417B1 (hu) * | 2006-10-26 | 2016-05-30 | Egis Gyógyszergyár Zrt | Eljárás desloratadine szén-dioxiddal képezett adduktjának előállítására |
| EP2164470A1 (en) * | 2007-05-11 | 2010-03-24 | ratiopharm GmbH | Pharmaceutical composition comprising desloratadine |
| EP2269586B1 (en) | 2009-07-01 | 2011-09-21 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical composition comprising desloratadine |
| PT2568970T (pt) | 2010-05-10 | 2019-02-11 | Lesvi Laboratorios Sl | Formulações farmacêuticas estáveis contendo um anti-histamínico |
| EP2727592A1 (en) | 2012-11-05 | 2014-05-07 | Kücükgüzel, Sükriye Güniz | A combination of desloratadine and paracetamol |
| CN103755682A (zh) * | 2013-12-30 | 2014-04-30 | 山东达因海洋生物制药股份有限公司 | 一种地氯雷他定新晶型及制备方法 |
| CN108358892A (zh) * | 2018-04-11 | 2018-08-03 | 常州方圆制药有限公司 | 一种地氯雷他定粗品的提纯方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985003707A1 (en) * | 1984-02-15 | 1985-08-29 | Schering Corporation | 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS |
| EP0208855B1 (en) * | 1985-05-13 | 1991-03-06 | Schering Corporation | process for preparing piperidylidene dihydrodibenzo(a,d)cycloheptenes and aza derivatives thereof, compounds obtained by such process and the use of such compounds for preparing useful pharmaceutical compositions |
| IE68935B1 (en) * | 1990-06-22 | 1996-07-24 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use |
-
1998
- 1998-01-07 UA UA2000010519A patent/UA62976C2/uk unknown
- 1998-07-01 PL PL98337712A patent/PL337712A1/xx unknown
- 1998-07-01 AT AT98932930T patent/ATE239010T1/de not_active IP Right Cessation
- 1998-07-01 EP EP98932930A patent/EP0993455B1/en not_active Expired - Lifetime
- 1998-07-01 IL IL13338798A patent/IL133387A/en not_active IP Right Cessation
- 1998-07-01 ES ES98932930T patent/ES2197480T3/es not_active Expired - Lifetime
- 1998-07-01 BR BR9811658-4A patent/BR9811658A/pt not_active IP Right Cessation
- 1998-07-01 CO CO98037139A patent/CO4940423A1/es unknown
- 1998-07-01 AR ARP980103203A patent/AR013161A1/es unknown
- 1998-07-01 KR KR1019997012456A patent/KR20010014316A/ko not_active Ceased
- 1998-07-01 HU HU0004308A patent/HUP0004308A3/hu unknown
- 1998-07-01 CN CN98806712A patent/CN1261886A/zh active Pending
- 1998-07-01 TR TR1999/03308T patent/TR199903308T2/xx unknown
- 1998-07-01 RU RU2000102669/04A patent/RU2197485C2/ru not_active IP Right Cessation
- 1998-07-01 NZ NZ501417A patent/NZ501417A/xx unknown
- 1998-07-01 DE DE69814076T patent/DE69814076T2/de not_active Expired - Lifetime
- 1998-07-01 JP JP50726599A patent/JP2002507991A/ja active Pending
- 1998-07-01 AU AU82710/98A patent/AU734487B2/en not_active Ceased
- 1998-07-01 CA CA002294352A patent/CA2294352C/en not_active Expired - Fee Related
- 1998-07-01 WO PCT/US1998/013433 patent/WO1999001450A1/en not_active Ceased
- 1998-07-01 ZA ZA985783A patent/ZA985783B/xx unknown
- 1998-07-01 SK SK1852-99A patent/SK185299A3/sk unknown
- 1998-07-02 MY MYPI98003024A patent/MY132943A/en unknown
- 1998-07-02 PE PE1998000594A patent/PE86399A1/es not_active Application Discontinuation
-
1999
- 1999-12-29 NO NO996547A patent/NO996547L/no not_active Application Discontinuation
-
2009
- 2009-07-27 JP JP2009174701A patent/JP2009242436A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0004308A3 (en) | 2004-07-28 |
| EP0993455A1 (en) | 2000-04-19 |
| DE69814076T2 (de) | 2004-02-26 |
| SK185299A3 (en) | 2000-07-11 |
| AR013161A1 (es) | 2000-12-13 |
| PL337712A1 (en) | 2000-08-28 |
| PE86399A1 (es) | 1999-10-23 |
| ES2197480T3 (es) | 2004-01-01 |
| ATE239010T1 (de) | 2003-05-15 |
| BR9811658A (pt) | 2000-09-05 |
| UA62976C2 (en) | 2004-01-15 |
| HUP0004308A2 (hu) | 2001-10-28 |
| CN1261886A (zh) | 2000-08-02 |
| MY132943A (en) | 2007-10-31 |
| JP2002507991A (ja) | 2002-03-12 |
| CO4940423A1 (es) | 2000-07-24 |
| NO996547L (no) | 2000-03-01 |
| ZA985783B (en) | 1999-01-19 |
| AU8271098A (en) | 1999-01-25 |
| NZ501417A (en) | 2000-10-27 |
| NO996547D0 (no) | 1999-12-29 |
| TR199903308T2 (xx) | 2000-11-21 |
| WO1999001450A1 (en) | 1999-01-14 |
| IL133387A (en) | 2004-02-08 |
| DE69814076D1 (de) | 2003-06-05 |
| HK1024687A1 (en) | 2000-10-20 |
| AU734487B2 (en) | 2001-06-14 |
| JP2009242436A (ja) | 2009-10-22 |
| IL133387A0 (en) | 2001-04-30 |
| CA2294352A1 (en) | 1999-01-14 |
| CA2294352C (en) | 2008-05-06 |
| RU2197485C2 (ru) | 2003-01-27 |
| EP0993455B1 (en) | 2003-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6506767B1 (en) | 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine | |
| JP2009242436A (ja) | ８−クロロ−６，１１−ジヒドロ−１１−（４−ピペリジリデン）−５Ｈ−ベンゾ［５，６］シクロヘプタ［１，２−ｂ］ピリジンの多形物 | |
| DE69109871T2 (de) | Pyridin- und pyridin-n-oxid-derivate von diarylmethyl- piperidinen oder piperazinen, deren zusammensetzungen und anwendung. | |
| JP2863629B2 (ja) | 置換ベンゾ〔５，６〕シクロヘプタピリジンの複素環式ｎ―オキシド誘導体、組成物およびその使用法 | |
| DE69418789T2 (de) | 2-(Piperidin-4-yl, Pyridin-4-yl und Tetrahydropyridin-4-yl)-benzofuran-7-carbamat Derivate, ihre Herstellung und Verwendung als Acetylcholinesterase Inhibitoren | |
| JPS6360968A (ja) | キノリン誘導体 | |
| DE69601527T2 (de) | Pyrrolylbenzimidazol-Derivate | |
| JP2961013B2 (ja) | 〔（アリールアルキルピペリジン−４−イル）メチル〕−２ａ，３，４，５−テトラヒドロ−１（２Ｈ）−アセナフチレン−１−オン類および関連化合物 | |
| DE69310904T2 (de) | Verbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung | |
| DE69014730T2 (de) | (1,2,3,4-Tetrahydro-9-acridinimino)cyclohexan-Carbonsäure und verwandte Verbindungen, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente. | |
| DE69800092T2 (de) | Substituierte 4-(6-fluor-[1H]-indol-3-yl)1,2,3,6-Tetrahydropyridin-Derivate für die Behandlung von ZNS-Störungen | |
| KR100235506B1 (ko) | 5-아미노-5,6,7,8-테트라하이드로퀴놀린 및 관련화합물,이의 제조방법 및 약제로서의 이의 용도 | |
| DE69515498T2 (de) | Naphthyridinderivate | |
| JP2791069B2 (ja) | シクロオクタン神経保護剤 | |
| DE69707504T2 (de) | Diphenylalkyl-tetrahydropyridine, verfahren zu ihren herstellung und diese enthaltende arzneimittel | |
| KR100586670B1 (ko) | 테트라히드로피리딘 유도체의 결정화 방법 및 이로 생성된 결정 형태 | |
| HRP920778A2 (en) | Novel 1-oxa-2-oxo-8-azaspiro74,5/ decane derivatives, pharmaceutical preparations containing them and process for the preparation thereof | |
| HK1024687B (en) | Polymorphs of 8-chloro-6, 11-dihydro-11-(4-piperidylidene) -5h-benzo[5,6] cyclohepta[1,2-b]pyridine | |
| MXPA00000133A (en) | POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6]CYCLOHEPTA[1, 2-b]PYRIDINE | |
| CA2615842A1 (en) | Polymorphs of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine | |
| CZ460399A3 (cs) | Polymorfy 8-chlor-6,ll-dihydro-ll-(4- piperidy!iden)-5Hbenzo/5,6/cyklohepta/l,2-b/pyridinu | |
| US5149813A (en) | Process for (1,2,3,4-tetrahydro-9-acridinimino)cyclohexane carboxylic acid and related compounds | |
| US5089615A (en) | Compound, 5,6,7,8-tetrahydro-1-(1,2,3,4-acridin-9-yl)-2H-3,1-benzoxazine-2,4-(1H)dione | |
| US5126449A (en) | (1,2,3,4-Tetrahydro-9-acridinimino)cyclohexane carboxylic acid and related compounds | |
| SE463716B (sv) | 2-halonicergolinderivat, foerfarande foer framstaellning av detta och en farmaceutisk beredning |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19991229 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20030623 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20050629 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20051011 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20050629 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |